Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Gengdu Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4287-4414; OpenAlex author ID A5025526415. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2026.218560↗
  2. HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer. Co-author DOI 10.1016/j.molcel.2026.06.022↗
  3. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  4. BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. Co-author DOI 10.7150/ijbs.104977↗
  5. Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. Co-author DOI 10.1016/j.bbadis.2024.167183↗
  6. ITGA2 overexpression inhibits DNA repair and confers sensitivity to radiotherapies in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215855↗
  7. HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-21-4362↗
  8. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
  9. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. First author PMID 33042621↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 8 shared papers, 2020–2026 · strength 1.43
  2. Yingke Zhou · 7 shared papers, 2022–2026 · strength 1.31
  3. Haixin Yu · 5 shared papers, 2022–2026 · strength 1.02
  4. Shanmiao Gou · 3 shared papers, 2025–2026 · strength 0.72
  5. Dianyun Ren · 5 shared papers, 2020–2024 · strength 0.70
  6. Penglin Pan · 4 shared papers, 2022–2026 · strength 0.69
  7. Taoyu Chen · 3 shared papers, 2022–2026 · strength 0.62
  8. Jingyuan Zhao · 3 shared papers, 2020–2024 · strength 0.43
  9. Yan Sun · 3 shared papers, 2020–2024 · strength 0.43
  10. Yuhan Zhao · 2 shared papers, 2024–2025 · strength 0.41
  11. Yi Zhou · 1 shared paper, 2026 · strength 0.28
  12. Tao Yin · 1 shared paper, 2026 · strength 0.26
  13. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  14. Hongkun Cai · 1 shared paper, 2026 · strength 0.26
  15. Xin Jin · 2 shared papers, 2020–2022 · strength 0.25
  16. Hongkun Cai · 1 shared paper, 2024 · strength 0.18
  17. Chen Zhou · 1 shared paper, 2022 · strength 0.14
  18. Shikai Zhu · 1 shared paper, 2022 · strength 0.14
  19. Jian Shen · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.